RE:RE:Q4 results
I would do the exact opposite. Medicure needs a catalyst--and Apicore isn't it. The Aggrastat patent ends in seven years--and Medicure needs to be ahead of the curve. I would focus all resources on getting the transdermal patch onto the market.